(Q84971393)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Tumor necrosis factor-alpha antagonist-induced sarcoidosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Tumor Necrosis Factor-Alpha Antagonist-Induced Sarcoidosis (English)

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

4 July 2024

author name string

Rochelle Robicheaux Clementine

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Justin Lyman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jerald Zakem

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jyothi Mallepalli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Stephen Lindsey

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Robert Quinet

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20808167

4 July 2024

publication date

1 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

13 February 2020

http://journals.lww.com/00124743-201009000-00004

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Journal of Clinical Rheumatology

4 July 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

274-279

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

The immunology of sarcoidosis

13 February 2020

cites work

1

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?

4 July 2024

2

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

4 July 2024

Treatment of sarcoidosis

4

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis

4 July 2024

5

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Treatment of sarcoidosis with infliximab

4 July 2024

6

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement

4 July 2024

7

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Development of sarcoidosis during etanercept therapy

4 July 2024

10

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Relapse of sarcoidosis upon treatment with etanercept

4 July 2024

11

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Granulomatous hepatitis associated with etanercept therapy.

4 July 2024

12

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients

4 July 2024

13

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Pulmonary sarcoidosis associated with etanercept therapy

4 July 2024

14

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Pulmonary sarcoidosis developing during infliximab therapy

4 July 2024

16

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Development of sarcoidosis during etanercept therapy

4 July 2024

17

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Granulomatous lung disease occurring during etanercept treatment

4 July 2024

18

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy

4 July 2024

19

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Lung injury linked to etanercept therapy

4 July 2024

20

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Tumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis

4 July 2024

21

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis

4 July 2024

22

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

TNF-R1 signaling: a beautiful pathway

4 July 2024

23

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells

4 July 2024

24

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo.

4 July 2024

25

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells.

4 July 2024

26

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

The immune paradox of sarcoidosis and regulatory T cells

4 July 2024

27

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Autoimmune Diseases Induced by TNF-Targeted Therapies

4 July 2024

28

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

4 July 2024

29

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

4 July 2024

30

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Off-target activity of TNF-alpha inhibitors characterized by protein biochips

4 July 2024

31

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Increased levels of serum interferon-gamma in pulmonary sarcoidosis and relationship with response to corticosteroid therapy

4 July 2024

32

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection

4 July 2024

33

1 reference

https://api.crossref.org/works/10.1097/RHU.0B013E3181EFA190

4 July 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808167%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference